-
1
-
-
33748935930
-
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors
-
doi:10.10l6/j.jaad.2005.10.010
-
Agero, A. L., Dusza, S. W., Benvenuto-Andrade, C, Busam, K. J., Myskowski, P., & Halpern, A. C. (2006). Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology, 55, 657-670. doi:10.10l6/j.jaad.2005.10.010
-
(2006)
Journal of the American Academy of Dermatology
, vol.55
, pp. 657-670
-
-
Agero, A.L.1
Dusza, S.W.2
Benvenuto-Andrade, C.3
Busam, K.J.4
Myskowski, P.5
Halpern, A.C.6
-
2
-
-
84872829895
-
-
Retrieved from
-
American Telemedicine Association. (2011). About telemedicine. Retrieved from http://www.americantelemed.org/i4a/pages/index.cfm?pageID=3308
-
(2011)
About Telemedicine
-
-
-
3
-
-
84984568870
-
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
-
MASCC Skin Toxicity Group, doi: 10.1007/S00520-011-1197-6
-
Lacouture, M., Anadkat, M. J., Bensadoun, R., Bryce, J., Chan, A., Epstein, J. B. MASCC Skin Toxicity Group. (2011). Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive Care in Cancer, 19, 1079-1095. doi: 10.1007/S00520-011- 1197-6
-
(2011)
Supportive Care in Cancer
, vol.19
, pp. 1079-1095
-
-
Lacouture, M.1
Anadkat, M.J.2
Bensadoun, R.3
Bryce, J.4
Chan, A.5
Epstein, J.B.6
-
4
-
-
33748466742
-
The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome
-
doi: 10.1111/j.1365-21332006.07452.x
-
Lacouture, M. E., & Lai, S. E. (2006). The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. British Journal of Dermatology, 155, 852-854. doi: 10.1111/j.1365-21332006.07452.x
-
(2006)
British Journal of Dermatology
, vol.155
, pp. 852-854
-
-
Lacouture, M.E.1
Lai, S.E.2
-
5
-
-
38849178281
-
Clinical approaches to minimize rash associated with EGFR inhibitors
-
doi:10.1188/08. ONF.103-111
-
Oishi, K. (2008). Clinical approaches to minimize rash associated with EGFR inhibitors. Oncology Nursing Forum, 35, 103-111. doi:10.1188/08. ONF.103-111
-
(2008)
Oncology Nursing Forum
, vol.35
, pp. 103-111
-
-
Oishi, K.1
-
6
-
-
24044500971
-
Clinical signs, pathophysiology, and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
-
doi:10.1093/annonc/mdi279
-
Segaert, S., & Van Cutsem, E. (2005). Clinical signs, pathophysiology, and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of Oncology, 16, 1425-1433. doi:10.1093/annonc/mdi279
-
(2005)
Annals of Oncology
, vol.16
, pp. 1425-1433
-
-
Segaert, S.1
Van Cutsem, E.2
|